Responses to CAR T-cell therapy deepen over time for lymphoma – Healio
Responses to CAR T-cell therapy deepen over time for lymphomaHealioEarlier results from ZUMA-1 showed axicabtagene ciloleucel (Yescarta; Kite Pharma, Gilead) — an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy — induced significant clinical b… Continue reading
